This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

MannKind Migrates to Israel to Stave Off Bankruptcy

I'm often criticized for having nothing positive to say about MannKind, so let the record reflect that I believe the company going to Israel to raise money is smart.

Anavex Presents Meaningless Results in Alzheimer's Drug Study

'The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%,' said Dr. Adam Kline, a researcher who reviewed the data.

ImmunoGen Refines Drug Targeting for Ovarian Cancer Patients

Ovarian cancer patients with tumors expressing high levels of a specific protein on their surface respond best to treatment with ImmunoGen's "smart bomb" cancer drug.

Agios Extends Reach of Cancer Metabolism Drug into Solid Tumors

New results from a study of Agios' AG-120 in patients with solid tumors were presented at a medical meeting Sunday.

Juno, Kite, Novartis Yelp 'Oh Merde!' at Cellectis Off-the-Shelf CAR-T Data

Can Cellectis transform CAR-T from a cool cancer science experiment into a profitable business?

Bluebird Gene Therapy Narrative Shift: 'Cure' May Elude Some Patients

Bluebird Bio is learning differences in the genetic mutation behind beta-thalassemia, a serious, inherited blood disease, is playing a role in how well patients respond to its experimental gene therapy.

FDA Letter Raises Questions About Biomarin Handling of Muscular Dystrophy Drug

Biomarin hasn't started confirmatory trials of DMD drug drisapersen suggested by FDA regulators.

Shire to Acquire Dyax for $5.9 Billion to Bolster Rare Disease Drug Business

Th purchase of Dyax strengthens Shire's portfolio of drugs treating a rare swelling disorder.

MannKind Afrezza Sales Flop Again, Sanofi Losing Patience

MannKind's signature product contributed only €2 million to Sanofi's diabetes sales in the third quarter.

Pfizer-Allergan Merger Would Spark Debate on U.S. Corporate Taxes

Lowering its corporate tax burden is a key motivating factor for New York-based Pfizer in any blockbuster deal with Allergan.

Page 2 of 347
Top Rated Stocks Top Rated Funds Top Rated ETFs